Giuseppe
Emeritus
Antimicrob Agents Chemother. 2008 Sep 29. [Epub ahead of print]
Therapeutic activity of an antiidiotypic antibody-derived killer peptide against influenza A virus experimental infection.
Conti G, Magliani W, Conti S, Nencioni L, Sgarbanti R, Palamara AT, Polonelli L. - Department of Pathology and Laboratory Medicine, Microbiology Section, University of Parma, Viale A. Gramsci 14, 43100 Parma, Italy; Department of Public Health Sciences, Pharmaceutical Microbiology Section, University of Rome "La Sapienza", P.le Aldo Moro 5, 00185, Rome, Italy.
The in vitro and in vivo activity against influenza A virus of a killer decapeptide (KP) is described and the mechanisms of action are suggested.
KP represents the functional internal image of a yeast killer toxin that proved to exert antimicrobial and anti-HIV-1 activity.
Treatment with KP demonstrated a significant inhibitory activity on the replication of two strains of influenza A virus in different cell lines, as evaluated by hemagglutination, hemadsorption and plaque assays.
A complete inhibition of virus particles production and a marked reduction of the synthesis of viral proteins (M1 and HA in particular) were observed at KP concentration of 4 microg/ml.
Moreover, KP administered intraperitoneally at a dose of 100 microg/mice/once a day for ten days to influenza NWS virus-infected mice, improved by 40% the survival of animals and significantly decreased the viral titers in the lungs.
Overall, KP appears to be the first antiidiotypic antibody-derived peptide displaying inhibitory activity and potential therapeutic effect against pathogenic microorganisms, HIV-1 and influenza A virus by different mechanisms of action.
PMID: 18824612 [PubMed - as supplied by publisher
-
------
Therapeutic activity of an antiidiotypic antibody-derived killer peptide against influenza A virus experimental infection.
Conti G, Magliani W, Conti S, Nencioni L, Sgarbanti R, Palamara AT, Polonelli L. - Department of Pathology and Laboratory Medicine, Microbiology Section, University of Parma, Viale A. Gramsci 14, 43100 Parma, Italy; Department of Public Health Sciences, Pharmaceutical Microbiology Section, University of Rome "La Sapienza", P.le Aldo Moro 5, 00185, Rome, Italy.
The in vitro and in vivo activity against influenza A virus of a killer decapeptide (KP) is described and the mechanisms of action are suggested.
KP represents the functional internal image of a yeast killer toxin that proved to exert antimicrobial and anti-HIV-1 activity.
Treatment with KP demonstrated a significant inhibitory activity on the replication of two strains of influenza A virus in different cell lines, as evaluated by hemagglutination, hemadsorption and plaque assays.
A complete inhibition of virus particles production and a marked reduction of the synthesis of viral proteins (M1 and HA in particular) were observed at KP concentration of 4 microg/ml.
Moreover, KP administered intraperitoneally at a dose of 100 microg/mice/once a day for ten days to influenza NWS virus-infected mice, improved by 40% the survival of animals and significantly decreased the viral titers in the lungs.
Overall, KP appears to be the first antiidiotypic antibody-derived peptide displaying inhibitory activity and potential therapeutic effect against pathogenic microorganisms, HIV-1 and influenza A virus by different mechanisms of action.
PMID: 18824612 [PubMed - as supplied by publisher
-
------